Cardurion Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing treatments for cardiovascular and metabolic diseases. The Company’s lead candidate is a small-molecule currently enrolled in two Phase 2 Heart Failure (“HF”) trials (HFrEF and HFpEF); the Company's secondary asset is a small-molecule for rare arrhythmias. Cardurion’s lead candidate has demonstrated early evidence of superior efficacy relative to current HF medications (and enhanced efficacy when used in combination with).
Status: Active
Announcement Date: July 2024